RESUMEN
BACKGROUND: Antimicrobial peptides have attracted much attention as a member of disease-associated molecules in systemic sclerosis (SSc), which is pathologically characterized by immune abnormalities, vasculopathy and tissue fibrosis. OBJECTIVE: To investigate the potential contribution of one of the antimicrobial peptide psoriasin to the development of SSc. METHODS: Psoriasin expression in the skin samples and sera derived from SSc patients and its correlation with clinical parameters were analysed. Psoriasin expression was evaluated by immunohistochemistry with skin samples from SSc patients and healthy controls. Serum levels of psoriasin were determined by enzyme-linked immunosorbent assay in 51 SSc patients and 19 healthy controls and assessed for the association with clinical symptoms. RESULTS: The expression of psoriasin was elevated in the epidermis of SSc lesional skin. Serum psoriasin levels were higher in SSc patients, especially in diffuse cutaneous SSc patients with disease duration of <6 years, than in healthy controls. With respect to clinical association, SSc patients with interstitial lung disease, telangiectasia and pitting scars had significantly augmented levels of serum psoriasin than those without each of these symptoms. In the subgroup of patients with interstitial lung disease, the elevation of serum psoriasin levels was associated with higher ground-glass opacity scores. Furthermore, serum psoriasin levels were decreased after the treatment with intravenous cyclophosphamide pulse as compared to baseline values. CONCLUSION: Our findings indicate a possible contribution of psoriasin to the development of clinical symptoms associated with vascular and epithelial abnormalities and inflammation in SSc, further supporting the roles of antimicrobial peptides in the SSc pathogenesis.
Asunto(s)
Cicatriz/sangre , Enfermedades Pulmonares Intersticiales/sangre , Proteína A7 de Unión a Calcio de la Familia S100/sangre , Esclerodermia Sistémica/sangre , Telangiectasia/sangre , Adulto , Anciano , Estudios de Casos y Controles , Cicatriz/etiología , Ciclofosfamida/uso terapéutico , Femenino , Humanos , Inmunosupresores/uso terapéutico , Enfermedades Pulmonares Intersticiales/diagnóstico por imagen , Enfermedades Pulmonares Intersticiales/etiología , Masculino , Persona de Mediana Edad , Radiografía Torácica , Proteína A7 de Unión a Calcio de la Familia S100/metabolismo , Esclerodermia Sistémica/complicaciones , Esclerodermia Sistémica/tratamiento farmacológico , Esclerodermia Sistémica/metabolismo , Piel/metabolismo , Telangiectasia/etiologíaRESUMEN
BACKGROUND: Endothelial protein C receptor (EPCR), expressed predominantly on endothelial cells, plays a critical role in the regulation of the coagulation system and also mediates various cytoprotective effects by binding and activating protein C. So far, the role of EPCR has not been studied in systemic sclerosis (SSc). OBJECTIVES: To investigate the potential contribution of EPCR to the development of SSc. METHODS: EPCR expression was examined in skin samples and cultivated dermal microvascular endothelial cells by immunostaining, immunoblotting and/or quantitative reverse-transcription polymerase chain reaction. Fli1, binding to the PROCR promoter, was assessed by chromatin immunoprecipitation. Serum EPCR levels were determined by enzyme-linked immunosorbent assay in 65 patients with SSc and 20 healthy subjects. RESULTS: EPCR expression was decreased in dermal small vessels of SSc lesional skin compared with those of healthy control skin. Transcription factor Fli1, deficiency of which is implicated in SSc vasculopathy, occupied the PROCR promoter, and EPCR expression was suppressed in Fli1 small interfering RNA-treated endothelial cells and dermal small vessels of Fli1(+/-) mice. In patients with SSc, decreased serum EPCR levels were associated with diffuse skin involvement, interstitial lung disease and digital ulcers. Furthermore, serum EPCR levels inversely correlated with plasma levels of plasmin-α2-plasmin inhibitor complex (PIC). Importantly, bosentan significantly reversed circulating EPCR and PIC levels in patients with SSc, and the expression of Fli1 and EPCR in dermal small vessels was elevated in patients treated with bosentan compared with untreated patients. CONCLUSIONS: Endothelial EPCR downregulation due to Fli1 deficiency may contribute to hypercoagulation status leading to tissue fibrosis and impaired peripheral circulation in SSc.
Asunto(s)
Antígenos CD/fisiología , Proteína Proto-Oncogénica c-fli-1/deficiencia , Receptores de Superficie Celular/fisiología , Esclerodermia Sistémica/etiología , Adulto , Anciano , Análisis de Varianza , Animales , Bleomicina/farmacología , Bosentán , Estudios de Casos y Controles , Células Cultivadas , Regulación hacia Abajo/fisiología , Células Endoteliales/metabolismo , Receptor de Proteína C Endotelial , Antagonistas de los Receptores de Endotelina/farmacología , Endotelio Vascular/metabolismo , Ensayo de Inmunoadsorción Enzimática , Femenino , Fibrinolisina/efectos de los fármacos , Humanos , Masculino , Ratones , Microvasos/metabolismo , Persona de Mediana Edad , Esclerodermia Sistémica/sangre , Sulfonamidas/farmacología , Trombofilia/etiología , alfa 2-Antiplasmina/efectos de los fármacosRESUMEN
BACKGROUND: LL-37 is an antimicrobial peptide with pleiotropic effects on the immune system, angiogenesis and tissue remodelling. These are cardinal pathological events in systemic sclerosis (SSc). OBJECTIVES: To elucidate the potential role of LL-37 in SSc. METHODS: The expression of target molecules was evaluated by immunostaining and quantitative reverse-transcription real-time polymerase chain reaction in human and murine skin. The mechanisms regulating LL-37 expression in endothelial cells were examined by gene silencing and chromatin immunoprecipitation. Serum LL-37 levels were determined by enzyme-linked immunosorbent assay. RESULTS: In SSc lesional skin, LL-37 expression was increased in dermal fibroblasts, perivascular inflammatory cells, keratinocytes and, particularly, dermal small vessels. Expression positively correlated with interferon-α expression, possibly reflecting LL-37-dependent induction of interferon-α. In SSc animal models, bleomycin-treated skin exhibited the expression pattern of CRAMP, a murine homologue of LL-37, similar to that of LL-37 in SSc lesional skin. Furthermore, Fli1+/- mice showed upregulated expression of CRAMP in dermal small vessels. Fli1 binding to the CAMP (LL-37 gene) promoter and Fli1 deficiency-dependent induction of LL-37 were also confirmed in human dermal microvascular endothelial cells. In the analysis of sera, patients with SSc had serum LL-37 levels significantly higher than in healthy controls. Furthermore, serum LL-37 levels positively correlated with skin score and the activity of alveolitis and were significantly elevated in patients with digital ulcers compared with those without. CONCLUSIONS: LL-37 upregulation, induced by Fli1 deficiency at least in endothelial cells, potentially contributes to the development of skin sclerosis, interstitial lung disease and digital ulcers in SSc.
Asunto(s)
Catelicidinas/fisiología , Esclerodermia Sistémica/etiología , Piel/patología , Enfermedades Vasculares/etiología , Adulto , Anciano , Animales , Péptidos Catiónicos Antimicrobianos/metabolismo , Catelicidinas/metabolismo , Células Endoteliales/metabolismo , Femenino , Fibrosis/sangre , Fibrosis/etiología , Humanos , Interferón-alfa/metabolismo , Ratones Endogámicos C57BL , Persona de Mediana Edad , Proteína Proto-Oncogénica c-fli-1/deficiencia , Esclerodermia Sistémica/sangre , Regulación hacia Arriba/fisiología , Enfermedades Vasculares/sangreRESUMEN
BACKGROUND: Lipocalin-2 is an adipocytokine implicated in apoptosis, innate immunity, angiogenesis, and the development of chronic kidney disease. OBJECTIVES: To investigate the role of lipocalin-2 in systemic sclerosis (SSc). MATERIALS AND METHODS: Serum lipocalin-2 levels were determined by enzyme-linked immunosorbent assay in 50 patients with SSc and 19 healthy subjects. Lipocalin-2 expression was evaluated in the skin of patients with SSc and bleomycin (BLM)-treated mice and in Fli1-deficient endothelial cells by reverse transcriptase-real time polymerase chain reaction, immunoblotting and/or immunohistochemistry. RESULTS: Although serum lipocalin-2 levels were comparable between patients with SSc and healthy controls, the prevalence of scleroderma renal crisis was significantly higher in patients with SSc with elevated serum lipocalin-2 levels than in those with normal levels. Furthermore, serum lipocalin-2 levels inversely correlated with estimated glomerular filtration rate in patients with SSc with renal dysfunction. Among patients with SSc with normal renal function, serum lipocalin-2 levels positively correlated with skin score in patients with diffuse cutaneous SSc with disease duration of < 3 years and inversely correlated with estimated right ventricular systolic pressure in total patients with SSc. Importantly, in SSc lesional skin, lipocalin-2 expression was increased in dermal fibroblasts and endothelial cells. In BLM-treated mice, lipocalin-2 was highly expressed in dermal fibroblasts, but not in endothelial cells. On the other hand, the deficiency of transcription factor Fli1, which is implicated in SSc vasculopathy, induced lipocalin-2 expression in cultivated endothelial cells. CONCLUSIONS: Lipocalin-2 may be involved in renal dysfunction and dermal fibrosis of SSc. Dysregulated matrix metalloproteinase-9/lipocalin-2-dependent angiogenesis due to Fli1 deficiency may contribute to the development of pulmonary arterial hypertension associated with SSc.
Asunto(s)
Proteínas de Fase Aguda/fisiología , Lipocalinas/fisiología , Enfermedades Pulmonares/etiología , Proteínas Proto-Oncogénicas/fisiología , Insuficiencia Renal Crónica/etiología , Esclerodermia Sistémica/etiología , Piel/patología , Enfermedades Vasculares/etiología , Proteínas de Fase Aguda/metabolismo , Adulto , Anciano , Animales , Apoptosis/fisiología , Estudios de Casos y Controles , Femenino , Fibrosis/etiología , Fibrosis/patología , Fibrosis/fisiopatología , Tasa de Filtración Glomerular/fisiología , Humanos , Lipocalina 2 , Lipocalinas/metabolismo , Enfermedades Pulmonares/fisiopatología , Masculino , Ratones , Persona de Mediana Edad , Proteínas Proto-Oncogénicas/metabolismo , Esclerodermia Sistémica/patología , Esclerodermia Sistémica/fisiopatología , Enfermedades Cutáneas Vasculares/etiología , Enfermedades Cutáneas Vasculares/fisiopatología , Enfermedades Vasculares/patología , Enfermedades Vasculares/fisiopatologíaAsunto(s)
Enfermedades Pulmonares Intersticiales/diagnóstico por imagen , Miositis/diagnóstico , Esclerodermia Difusa/inmunología , Enfermedad Aguda , Anciano , Anticuerpos Anticitoplasma de Neutrófilos/inmunología , Anticuerpos Antinucleares/inmunología , Autoanticuerpos/inmunología , ADN-Topoisomerasas de Tipo I , Progresión de la Enfermedad , Electromiografía , Femenino , Humanos , Enfermedades Pulmonares Intersticiales/complicaciones , Enfermedades Pulmonares Intersticiales/inmunología , Enfermedades Pulmonares Intersticiales/fisiopatología , Imagen por Resonancia Magnética , Persona de Mediana Edad , Miositis/complicaciones , Miositis/inmunología , Proteínas Nucleares/inmunología , Ribonucleoproteína Nuclear Pequeña U1/inmunología , Esclerodermia Difusa/complicaciones , Tomografía Computarizada por Rayos XRESUMEN
BACKGROUND: Early lesions of localized scleroderma are histologically characterized by perivascular lymphocytic infiltrate in the reticular dermis and swollen endothelial cells. However, there have been few information regarding histological features other than these findings in localized scleroderma. OBJECTIVE: Since en coup de sabre (ECDS) is a certain subset of localized scleroderma with a relatively uniform clinical manifestation, we focused on this disease subset and evaluated its histopathological features. METHODS: A total of 16 patients with ECDS were retrospectively evaluated on the basis of clinical and histological findings. RESULTS: Regardless of clinical manifestations, vacuolar degeneration was found in all of the ECDS patients. Importantly, keratinocyte necroses were restricted to early and active ECDS lesions. In early ECDS patients (disease duration of <3 years), moderate to severe perivascular and/or periappendageal lymphocytic infiltrate and vacuolar changes in follicular epithelium were more prominent, whereas epidermal atrophy was less frequently observed, than in late ECDS patients (disease duration of ≥6 years). CONCLUSION: Vacuolar degeneration at the dermoepidermal junction is a common histological feature in ECDS and perivascular and/or periappendageal lymphocytic infiltrate and vacuolar degeneration of follicular epithelium are characteristic especially in early ECDS, further supporting a canonical idea that the elimination of mutated epidermal cells by immune surveillance contributes to tissue damage and resultant fibrosis in localized scleroderma.
Asunto(s)
Esclerodermia Localizada/patología , Adolescente , Adulto , Niño , Femenino , Humanos , Masculino , Persona de Mediana Edad , Adulto JovenRESUMEN
BACKGROUND: Retinol binding protein-4 (RBP-4) is a member of adipocytokines, which is potentially associated with fibrosis, vasodilation, and angiogenesis in addition to insulin resistance. OBJECTIVE: To investigate the clinical significance of serum RBP4 levels in patients with systemic sclerosis (SSc), which is a systemic autoimmune disease characterized by fibrosis and vasculopathy. METHODS: Serum RBP4 levels were determined by enzyme-linked immunosorbent assay in 62 SSc patients and 19 healthy controls. RESULTS: Similar to patients with chronic kidney disease, serum RBP4 levels inversely correlated with estimated glomerular filtration rate in SSc patients with renal dysfunction. Therefore, analyses were carried out by excluding SSc patients with estimated glomerular filtration rate <60 mL/min/1.73 m(2) . Serum RBP4 levels were significantly lower in diffuse cutaneous SSc (dcSSc) than in control subjects [median (25-75 percentile); 25.8 µg/mL (19.6-47.0) vs. 43.1 µg/mL (31.7-53.4), P < 0.05], while there was no significant difference between limited cutaneous SSc (lcSSc) [28.0 µg/mL (25.4-43.3)] and control subjects. In both of dcSSc and lcSSc, patients with Raynaud's phenomenon had RBP4 levels significantly lower than those without. Furthermore, serum RBP4 levels inversely correlated with pulmonary function test results in dcSSc and with right ventricular systolic pressure in lcSSc. CONCLUSION Decreased RBP4 levels are associated with the prevalence of Raynaud's phenomenon in dcSSc and lcSSc, with the severity of interstitial lung disease in dcSSc, and with the degree of pulmonary vascular involvement in lcSSc, suggesting the possible contribution of RBP4 to the pathological events in this disorder.
Asunto(s)
Proteínas Plasmáticas de Unión al Retinol/metabolismo , Esclerodermia Sistémica/sangre , Ciclofosfamida/uso terapéutico , Ensayo de Inmunoadsorción Enzimática , Femenino , Tasa de Filtración Glomerular , Humanos , Enfermedades Pulmonares Intersticiales/sangre , Masculino , Persona de Mediana Edad , Enfermedad de Raynaud/sangre , Esclerodermia Sistémica/tratamiento farmacológico , Esclerodermia Sistémica/fisiopatologíaRESUMEN
BACKGROUND: A disintegrin and metalloprotease (ADAM) 12 is one of the metalloproteinase-type ADAMs and possesses extracellular metalloprotease and cell-binding functions. ADAM12 is expressed in two alternative forms, such as a membrane-anchored form (ADAM12-L) and a short secreted form (ADAM12-S). OBJECTIVE: To investigate the clinical significance of serum ADAM12-S levels in systemic sclerosis (SSc). METHODS: Serum ADAM12-S levels were determined by a specific enzyme-linked immunosorbent assay in 61 SSc patients and 18 healthy controls. RESULTS: Serum ADAM12-S levels were significantly increased in diffuse cutaneous SSc (dcSSc) patients than in healthy controls (0.417 ± 0.389 vs. 0.226 ± 0.065 ng/mL; P < 0.05), while being comparable between limited cutaneous SSc (0.282 ± 0.258 ng/mL) and healthy controls. Serum ADAM12-S levels significantly elevated in dcSSc patients with disease duration of ≤ 6 years (0.537 ± 0.449 ng/mL, P < 0.05), but not in dcSSc with disease duration of >6 years (0.225 ± 0.049 ng/mL), compared to healthy controls. Furthermore, in dcSSc patients with disease duration of ≤ 6 years, serum ADAM12-S levels correlated positively with modified Rodnan total skin thickness score, ground glass score, and serum C-reactive protein values, while showed inverse correlation with fibrosis score. CONCLUSION: Elevated serum ADAM12-S levels are associated with elevated serum inflammatory marker, severity of skin fibrosis, and activity of interstitial lung disease in dcSSc, suggesting the possible contribution of ADAM12-S to the pathological events in this disorder.
Asunto(s)
Proteínas ADAM/sangre , Enfermedades Pulmonares Intersticiales/sangre , Enfermedades Pulmonares Intersticiales/etiología , Proteínas de la Membrana/sangre , Esclerodermia Sistémica/sangre , Esclerodermia Sistémica/complicaciones , Proteína ADAM12 , Progresión de la Enfermedad , Femenino , Fibrosis/sangre , Fibrosis/etiología , Humanos , Masculino , Persona de Mediana Edad , Piel/patología , Factores de TiempoRESUMEN
BACKGROUND: Bosentan is an oral dual endothelin receptor antagonist, which has been shown to be efficacious for preventing new digital ulcers in patients with systemic sclerosis (SSc) in two high-quality randomized controlled trials. However, its efficacy for nondigital ulcers in SSc remains unknown. OBJECTIVES: To evaluate the efficacy of bosentan on nondigital ulcers in patients with SSc. METHODS: Bosentan was administered to five patients with SSc with pulmonary arterial hypertension, who also had nondigital ulcers refractory to conventional treatments. The efficacy of bosentan on nondigital ulcers and its association with clinical features of ulcers were analysed. RESULTS: The nondigital ulcers refractory to conventional treatments were significantly improved by the administration of bosentan in cases surrounded with severe cyanosis. In contrast, nondigital ulcers without cyanosis were still refractory to bosentan therapy. CONCLUSIONS: Bosentan may be efficacious for accelerating the healing of nondigital ulcers with severe cyanosis, suggesting that nondigital ulcers caused by severely impaired peripheral circulation are highly responsive to this treatment.
Asunto(s)
Antihipertensivos/uso terapéutico , Fármacos Dermatológicos/uso terapéutico , Úlcera del Pie/tratamiento farmacológico , Esclerodermia Sistémica/complicaciones , Sulfonamidas/uso terapéutico , Adulto , Anciano , Anciano de 80 o más Años , Bosentán , Femenino , Humanos , Hipertensión Pulmonar/tratamiento farmacológico , Persona de Mediana Edad , Uso Fuera de lo Indicado , Resultado del Tratamiento , Cicatrización de Heridas/efectos de los fármacosRESUMEN
BACKGROUND: The cell surface protein CD93, expressed on endothelial and myeloid cells, mediates phagocytosis, inflammation and cell adhesion. A soluble form of CD93 (sCD93) is released during inflammation. OBJECTIVES: To determine the serum sCD93 level and its association with clinical parameters in patients with systemic sclerosis (SSc). METHODS: Serum sCD93 levels were examined by enzyme-linked immunosorbent assay in 59 patients with SSc, 24 patients with systemic lupus erythematosus and 47 healthy individuals. The expression of CD93 in skin tissues was examined immunohistochemically. In a retrospective longitudinal study, sera from 11 patients with SSc were analysed. RESULTS: Serum sCD93 levels were increased in patients with SSc compared with healthy individuals (P<0·001). Patients with diffuse cutaneous SSc showed greater levels of sCD93 than those with limited cutaneous SSc (P<0·01) or systemic lupus erythematosus (P<0·01). Serum sCD93 levels correlated positively with the severity of skin sclerosis. Strong CD93 immunostaining was observed on endothelial cells in lesional skin tissues. In the longitudinal study, sCD93 levels decreased in parallel with improvement in skin sclerosis. CONCLUSIONS: Serum sCD93 levels are increased in patients with SSc and correlate with the severity and activity of skin sclerosis. CD93 may contribute to the development of skin fibrosis in SSc.
Asunto(s)
Glicoproteínas de Membrana/metabolismo , Receptores de Complemento/metabolismo , Esclerodermia Sistémica/sangre , Adolescente , Adulto , Anciano , Niño , Femenino , Humanos , Inmunohistoquímica , Estudios Longitudinales , Masculino , Persona de Mediana Edad , Piel/metabolismo , Adulto JovenRESUMEN
BACKGROUND: A noncanonical pathway of transforming growth factor-ß signalling, the c-Abl/protein kinase C-δ (PKC-δ)/Friend leukemia virus integration 1 (Fli1) axis, is a powerful regulator of collagen synthesis in dermal fibroblasts. OBJECTIVES: To investigate the significance of the c-Abl/PKC-δ/Fli1 pathway for the establishment of the profibrotic phenotype in lesional dermal fibroblasts from patients with localized scleroderma (LSc). METHODS: The activation status of the c-Abl/PKC-δ/Fli1 pathway was evaluated by immunoblotting and chromatin immunoprecipitation using cultured dermal fibroblasts from patients with LSc and closely matched healthy controls and by immunostaining on skin sections. The effects of a platelet-derived growth factor receptor inhibitor AG1296 and gene silencing of c-Abl on the expression levels of type I collagen were evaluated by immunoblotting. RESULTS: The phosphorylation levels of Fli1 at threonine 312 were increased, while the total Fli1 levels and the binding of Fli1 to the COL1A2 promoter were decreased, in cultured LSc fibroblasts compared with cultured normal fibroblasts. Furthermore, in cultured LSc fibroblasts, the expression levels of c-Abl were elevated compared with cultured normal fibroblasts and PKC-δ was preferentially localized in the nucleus. These findings were also confirmed in vivo by immunohistochemistry using skin sections. Moreover, gene silencing of c-Abl, but not AG1296, significantly suppressed the expression of type I collagen in cultured LSc fibroblasts. CONCLUSIONS: Constitutive activation of the c-Abl/PKC-δ/Fli1 pathway at least partially contributes to the establishment of the profibrotic phenotype in LSc dermal fibroblasts, which provides a novel molecular basis to explain the efficacy of imatinib against skin sclerosis in a certain subset of LSc.
Asunto(s)
Fibroblastos/metabolismo , Proteína Quinasa C-delta/metabolismo , Proteína Proto-Oncogénica c-fli-1/metabolismo , Proteínas Proto-Oncogénicas c-abl/metabolismo , Esclerodermia Localizada/metabolismo , Adolescente , Adulto , Benzamidas , Estudios de Casos y Controles , Células Cultivadas , Niño , Preescolar , Femenino , Fibroblastos/efectos de los fármacos , Humanos , Mesilato de Imatinib , Masculino , Persona de Mediana Edad , Fosforilación , Piperazinas/farmacología , Proteína Quinasa C-delta/genética , Inhibidores de Proteínas Quinasas/farmacología , Proteína Proto-Oncogénica c-fli-1/genética , Pirimidinas/farmacología , Esclerodermia Localizada/genética , Factor de Crecimiento Transformador beta/efectos de los fármacos , Factor de Crecimiento Transformador beta/genética , Factor de Crecimiento Transformador beta/metabolismoAsunto(s)
Factores Inmunológicos/uso terapéutico , Enfermedades Pulmonares Intersticiales/tratamiento farmacológico , Rituximab/uso terapéutico , Esclerodermia Sistémica/complicaciones , Femenino , Glucocorticoides/uso terapéutico , Humanos , Pulmón/diagnóstico por imagen , Enfermedades Pulmonares Intersticiales/diagnóstico por imagen , Enfermedades Pulmonares Intersticiales/etiología , Prednisolona/uso terapéutico , Tomografía Computarizada por Rayos X , Insuficiencia del Tratamiento , Resultado del Tratamiento , Adulto JovenRESUMEN
Systemic plasmacytosis is characterized by plasma cell proliferation in multiple organs including skin, and by polyclonal hypergammaglobulinaemia. Hyperviscosity-related retinopathy has never been described with this condition, to our knowledge. We report a case of systemic plasmacytosis in a 49-year-old Japanese woman, who presented with fever, multiple erythematous plaques, hypergammaglobulinaemia, renal failure and bilateral retinal haemorrhage. Reduction of immunoglobulin with oral steroid reversed the retinopathy related to hyperviscosity syndrome. When marked hypergammaglobulinaemia is found in a patient with systemic plasmacytosis, funduscopic examination should be performed to reveal early asymptomatic retinal changes, because the retinopathy is treatable by control of the underlying disease.
Asunto(s)
Viscosidad Sanguínea , Hipergammaglobulinemia/complicaciones , Células Plasmáticas/patología , Hemorragia Retiniana/etiología , Femenino , Enfermedades Hematológicas/complicaciones , Humanos , Persona de Mediana Edad , Enfermedades de la Piel/patología , SíndromeRESUMEN
Autophagy and the Cvt pathway are examples of nonclassical vesicular transport from the cytoplasm to the vacuole via double-membrane vesicles. Apg8/Aut7, which plays an important role in the formation of such vesicles, tends to bind to membranes in spite of its hydrophilic nature. We show here that the nature of the association of Apg8 with membranes changes depending on a series of modifications of the protein itself. First, the carboxy-terminal Arg residue of newly synthesized Apg8 is removed by Apg4/Aut2, a novel cysteine protease, and a Gly residue becomes the carboxy-terminal residue of the protein that is now designated Apg8FG. Subsequently, Apg8FG forms a conjugate with an unidentified molecule "X" and thereby binds tightly to membranes. This modification requires the carboxy-terminal Gly residue of Apg8FG and Apg7, a ubiquitin E1-like enzyme. Finally, the adduct Apg8FG-X is reversed to soluble or loosely membrane-bound Apg8FG by cleavage by Apg4. The mode of action of Apg4, which cleaves both newly synthesized Apg8 and modified Apg8FG, resembles that of deubiquitinating enzymes. A reaction similar to ubiquitination is probably involved in the second modification. The reversible modification of Apg8 appears to be coupled to the membrane dynamics of autophagy and the Cvt pathway.
Asunto(s)
Autofagia , Citoplasma/metabolismo , Proteínas Asociadas a Microtúbulos/metabolismo , Peroxisomas/metabolismo , Proteínas de Saccharomyces cerevisiae , Vacuolas/metabolismo , Secuencia de Aminoácidos , Familia de las Proteínas 8 Relacionadas con la Autofagia , Proteínas Relacionadas con la Autofagia , Transporte Biológico , Dominio Catalítico , Cisteína Endopeptidasas/metabolismo , Ligasas/metabolismo , Proteínas de la Membrana/metabolismo , Modelos Biológicos , Datos de Secuencia Molecular , Unión Proteica , Procesamiento Proteico-Postraduccional , Señales de Clasificación de Proteína , Homología de Secuencia de Aminoácido , Ubiquitina-Proteína Ligasas , Ubiquitinas/metabolismoAsunto(s)
Antineoplásicos/efectos adversos , Hidrocarburos Aromáticos con Puentes/efectos adversos , Células Endoteliales/metabolismo , Fibroblastos/metabolismo , Proteínas de Microfilamentos/metabolismo , Receptores Citoplasmáticos y Nucleares/metabolismo , Esclerodermia Sistémica/inducido químicamente , Taxoides/efectos adversos , Neoplasias de la Mama/tratamiento farmacológico , Femenino , Humanos , Inmunohistoquímica , Persona de Mediana Edad , Esclerodermia Sistémica/metabolismo , Piel/metabolismo , TransactivadoresRESUMEN
14.3.3 protein, a brain-specific protein, is an activator of tyrosine and tryptophan hydroxylases, key enzymes for biosynthesis of dopamine and serotonin. In this article, we describe cloning of cDNA for human brain 14.3.3 eta chain and expression of 14.3.3 eta chain mRNA in some human cultured cells. The cloned cDNA is 1730 bp long and contains 191 bp of a 5'-noncoding region, the complete 738 bp of coding region, and 801 bp of a 3'-noncoding region, containing three polyadenylation signals. This cDNA encoded a polypeptide of 246 amino acids (M(r) 28,196). Furthermore, using in situ hybridization histochemistry, the expression of mRNA for this protein was examined in the rat central nervous system. In situ hybridization histochemistry indicated that 14.3.3 eta chain mRNA is detected not only in the monoamine-synthetic neurons, but also in other neurons in the discrete nuclei, which synthesize neither cathecholamine nor serotonin. Northern blot analysis demonstrated that the addition of methamphetamine into the cultured medium increased the mRNA level for 14.3.3 eta chain in U-251 cells, but did not increase that of GFAP.
Asunto(s)
Encéfalo/metabolismo , Expresión Génica/efectos de los fármacos , Metanfetamina/farmacología , Neuronas/metabolismo , Biosíntesis de Proteínas , Tirosina 3-Monooxigenasa , Proteínas 14-3-3 , Adulto , Secuencia de Aminoácidos , Animales , Secuencia de Bases , Encéfalo/efectos de los fármacos , Línea Celular , Células Cultivadas , Corteza Cerebral/efectos de los fármacos , Corteza Cerebral/metabolismo , Clonación Molecular , ADN Complementario , Inhibidores Enzimáticos , Humanos , Hibridación in Situ , Sustancias Macromoleculares , Datos de Secuencia Molecular , Neuronas/efectos de los fármacos , ARN Mensajero/biosíntesis , ARN Mensajero/efectos de los fármacos , Ratas , Mapeo Restrictivo , Células Tumorales CultivadasRESUMEN
The structure of rat muscle-specific enolase (beta beta enolase) gene was determined. It comprises 12 exons of various lengths (59-223 bp) spanning about 6 kbp and its exon-intron organization is similar to that of neuron-specific enolase (gamma gamma enolase) gene. A transcriptional start site was identified by a combination of S1 nuclease mapping and primer extension analyses. In the 5'-flanking region we found a TATA-box-like sequence and several MyoD-binding motifs. The in vitro cell free transcription of the truncated genomic DNA fragment using HeLa cell extract showed that the transcription start site has been correctly identified and the promoter sequences work well.
Asunto(s)
Músculos/enzimología , Fosfopiruvato Hidratasa/genética , Secuencia de Aminoácidos , Animales , Secuencia de Bases , Clonación Molecular , Expresión Génica , Genes , Intrones , Datos de Secuencia Molecular , Ratas , Secuencias Reguladoras de Ácidos Nucleicos , Mapeo Restrictivo , Transcripción GenéticaRESUMEN
Chromosome fragmentation, ATP1 disruption, and Southern blot analyses of total DNAs and prime clones of chromosome II showed that three identical ATP1s are present, directing from the telomere to the centromere on the 35-55 kb far from the left telomere sequence of chromosome II. That is, the coding and 5'-, 3'-non-coding regions of ATP1 are repeated 3 times at approximately 7 kb intervals. These three ATP1s are expressed, and one and two ATP1s-disrupted strains, respectively, showed ca.70 and 40% decreases in their ATPase activities and alpha subunit contents, compared to those of the wild type, DC-5 or W303-1A strain, but could grow on glycerol.